Clearbridge Health (SGX:1H3) entered an initial five-year strategic alliance agreement with Guangdong Amoreneg Medicine and Research and Development, according to a Friday filing with the Singapore Exchange.
Under the agreement, the company will appoint Amoreneg Medicine as a consultant to provide advisory services on the establishment of a peripheral blood mononuclear cells processing and cryogenic facility.
The agreement will also see the company become Amoreneg Medicine's first distributor of its proprietary stem cell products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.